Barnett & Company’s Alexion Pharmaceuticals ALXN Stock Holding History

Barnett & Company’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-12	Closed	-$1K	–	514
2019 Q3	$1K	Buy	+12	New	+$1.35K	﹤0.01%	424

Other funds holding ALXN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Barnett & Company's ALXN Position: Q4 2019 in Review

Barnett & Company sold out of Alexion Pharmaceuticals (ALXN) in Q4 2019, closing a stake of 12 shares — an estimated $1K sold.

Barnett & Company first reported a position in ALXN in Q3 2019 and held it in 1 quarter. The position peaked at $1K in Q3 2019. 669 funds tracked by Wall St. Rank hold ALXN as of Q4 2019.

Barnett & Company reported no remaining Alexion Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
Barnett & Company sold 12 Alexion Pharmaceuticals shares in Q4 2019, an estimated $1K.
Barnett & Company first reported a position in Alexion Pharmaceuticals in Q3 2019 and held it in 1 quarter.
Barnett & Company's Alexion Pharmaceuticals position peaked at $1K in Q3 2019.
669 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2019.

Based on Barnett & Company's 13F filing for Q4 2019, filed 22 Jan 2020.